CA3068854A1 - Selective inhibitors of clinically important mutants of the egfr tyrosine kinase - Google Patents
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase Download PDFInfo
- Publication number
- CA3068854A1 CA3068854A1 CA3068854A CA3068854A CA3068854A1 CA 3068854 A1 CA3068854 A1 CA 3068854A1 CA 3068854 A CA3068854 A CA 3068854A CA 3068854 A CA3068854 A CA 3068854A CA 3068854 A1 CA3068854 A1 CA 3068854A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- alkoxy
- independently
- compound
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528697P | 2017-07-05 | 2017-07-05 | |
| US62/528,697 | 2017-07-05 | ||
| PCT/US2018/040904 WO2019010295A1 (en) | 2017-07-05 | 2018-07-05 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068854A1 true CA3068854A1 (en) | 2019-01-10 |
Family
ID=64950363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068854A Abandoned CA3068854A1 (en) | 2017-07-05 | 2018-07-05 | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200131176A1 (https=) |
| EP (1) | EP3648753A4 (https=) |
| JP (1) | JP2020526499A (https=) |
| KR (1) | KR20200028966A (https=) |
| CN (1) | CN111093645A (https=) |
| CA (1) | CA3068854A1 (https=) |
| WO (1) | WO2019010295A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726968B (zh) | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| JP7028900B2 (ja) * | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
| US20210101881A1 (en) * | 2018-02-12 | 2021-04-08 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Pyrimidine compound, preparation method thereof and medical use thereof |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| PT3943491T (pt) * | 2019-03-19 | 2025-07-28 | Voronoi Inc | Derivado de heteroarilo, método para a produção do mesmo e composição farmacêutica que compreende o mesmo como componente eficaz |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| WO2021067654A1 (en) | 2019-10-03 | 2021-04-08 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| TW202128670A (zh) * | 2019-11-26 | 2021-08-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮多環類衍生物抑制劑、其製備方法和應用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021243596A1 (en) * | 2020-06-03 | 2021-12-09 | InventisBio Co., Ltd. | Aminopyrimidine compounds, preparation methods and uses thereof |
| WO2022131741A1 (ko) * | 2020-12-14 | 2022-06-23 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| US20240226101A1 (en) * | 2021-04-30 | 2024-07-11 | Suzhou Puhe BioPharma Co., Ltd. | Pyrimidinylaminobenzenes for lung cancer treatment |
| CN115667251A (zh) | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
| CN113651800B (zh) * | 2021-09-07 | 2022-08-19 | 山东铂源药业股份有限公司 | 一种甲磺酸奥希替尼的制备方法 |
| CN115650974B (zh) * | 2022-08-04 | 2024-06-18 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用 |
| WO2024094064A1 (en) * | 2022-11-02 | 2024-05-10 | Suzhou Puhe Biopharma Co., Ltd | Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| WO2016105525A2 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| TWI726968B (zh) * | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| EP3492462B1 (en) * | 2016-07-26 | 2023-08-30 | Shenzhen TargetRx, Inc. | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
-
2018
- 2018-07-05 CN CN201880044480.8A patent/CN111093645A/zh active Pending
- 2018-07-05 EP EP18827860.0A patent/EP3648753A4/en not_active Withdrawn
- 2018-07-05 KR KR1020207003387A patent/KR20200028966A/ko not_active Withdrawn
- 2018-07-05 JP JP2019572412A patent/JP2020526499A/ja active Pending
- 2018-07-05 US US16/628,831 patent/US20200131176A1/en not_active Abandoned
- 2018-07-05 WO PCT/US2018/040904 patent/WO2019010295A1/en not_active Ceased
- 2018-07-05 CA CA3068854A patent/CA3068854A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3648753A4 (en) | 2021-03-17 |
| CN111093645A (zh) | 2020-05-01 |
| WO2019010295A1 (en) | 2019-01-10 |
| EP3648753A1 (en) | 2020-05-13 |
| KR20200028966A (ko) | 2020-03-17 |
| US20200131176A1 (en) | 2020-04-30 |
| JP2020526499A (ja) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3068854A1 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| EP3399968B1 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| JP6254169B2 (ja) | ベンズアミドおよびヘテロベンズアミド化合物 | |
| JP7118267B2 (ja) | がんの処置のためのＨＰＫ１阻害剤としての２，３－ジヒドロ－１Ｈ－ピロロ［３，４－ｃ］ピリジン－１－オン誘導体 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| KR102483020B1 (ko) | Tam 저해제로서의 피롤로트리아진 화합물 | |
| CN114394966A (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| KR20230003128A (ko) | Hpk1 억제제로서의 아잘락탐 화합물 | |
| AU2019363657B2 (en) | 5-azaindazole derivatives as adenosine receptor antagonists | |
| HK40057478B (zh) | Hpk1抑制剂及其使用方法 | |
| HK40017966A (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| HK40084694A (en) | Azalactam compounds as hpk1 inhibitors | |
| TW202005967A (zh) | Ｅｇｆｒ酪胺酸激酶之臨床上重要的突變體之選擇性抑制劑 | |
| HK40004229B (zh) | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 | |
| HK40004229A (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| HK40002986A (zh) | 吡啶并嘧啶酮cdk2/4/6抑制剂 | |
| OA17121A (en) | Macrocyclic derivatives for the treatment of proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240105 |